A population-based cohort study of HRT use and breast cancer in Korea

Asia-Pacific Journal of Public Health

Volumn 24, Issue 2, 2012, Pages 415-422

  Park, Sat Byul ^a,b   Shin, Hai Rim ^c,d   Lee, Soon Young ^a  

^a Ajou University School of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c National Cancer Center   (South Korea)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

breast cancer; hormone replacement therapy; menopausal syndrome

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MIDDLE AGED; REGISTER; RISK ASSESSMENT; SOUTH KOREA;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; REGISTRIES; REPUBLIC OF KOREA; RISK ASSESSMENT;

EID: 84859047903     PISSN: 10105395     EISSN: None     Source Type: Journal    
DOI: 10.1177/1010539510379392     Document Type: Article

References (42)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 ; 288: 321-333
2. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 ; 362: 419-427
3. Population and Housing Census Report 1995-2000. Seoul, South Korea: Korea National Statistical Office ; 2001:
4. Park TJ, Kim BS, Kim SY, et al. A study on primary care physician's execution of the postmenopausal hormone replacement therapy. J Korean Acad Fam Med. 1995 ; 16: 824-832
5. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999 ; 130: 545-553 (Pubitemid 29169381)
6. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG. 2002 ; 109: 1319-1330
7. Lee JH, Yim SH, Won YJ, et al. Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci. 2007 ; 22: S11 - S16
8. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004 ; 6: 229-239 (Pubitemid 39440251)
9. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer. 2006 ; 118: 2373-2378
10. Parkin DM, Whelan SL, Ferlay J, Storm H Cancer Incidence in Five Continents. Lyon, France: IARC ; 2002:
11. Shin HR, Jung KW, Won YJ, Park JG. 139 KCCR-Affiliated Hospitals. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat. 2004 ; 36: 103-114
12. Shin HR, Jun KW, Won YJ, et al. National cancer incidence for the year 2002 in Korea. Cancer Res Treat. 2007 ; 39: 139-149
13. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003 ; 39: 1718-1729 (Pubitemid 36897609)
14. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998 ; 6 (suppl 2). 51S - 209S
15. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008 ; 168: 370-377 (Pubitemid 351347128)
16. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993 ; 15: 36-47 (Pubitemid 23269069)
17. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 ; 280: 605
18. Grady D, Herriton D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen Progestin Replacement Study Follow-up (HERS-II). JAMA. 2002 ; 288: 49-57 (Pubitemid 34705518)
19. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA. 2004 ; 291: 1701-1712
20. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 ; 365: 1543-1551
21. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006 ; 24: e49 - e50
22. Ravdin PM, Cronin K, Howlander N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 ; 356: 1670-1674 (Pubitemid 46631679)
23. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilization of hormone replacement therapy. Breast Cancer Res Treat. 2008 ; 107: 427-430 (Pubitemid 351172118)
24. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008 ; 188: 641-644
25. Allemand H, Seradour B, Weill A, Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer. 2008 ; 95: 11-15 (Pubitemid 351265280)
26. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007 ; 25: 3437-3439 (Pubitemid 47310880)
27. Zahl PH, Maehlen J. A decline in breast cancer incidence. N Engl J Med. 2007 ; 357: 510-511
28. Vaidya JS. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 ; 100: 598-599
29. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007 ; 9: R28
30. MacMahon B, Cole P. Is the breast cancer incidence declining?. Epidemiology. 2008 ; 19: 268-269
31. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 ; 360: 573-587
32. Suh JS, Yoo KY, Kwon OJ, et al. Menstrual and reproductive factors related to the risk of breast cancer in Korea. Ovarian hormone effect on breast cancer. Korean J Med Sci. 1996 ; 11: 501-508 (Pubitemid 126702062)
33. Yoo KY, Park SK, Sung J, Kang DH, Kim YC, Kang HS. High risk group for female breast cancer in Korea. J Korean Cancer Assoc. 1998 ; 30: 435-449
34. Qi XY, Zhang AY, Wu GL, Pang WZ. The association between breast cancer and diet and other factors. Asia Pac J Public Health. 1994 ; 7: 98-104
35. Mustaffa BE. Healthy lifestyles in the new millennium. Asia Pac J Public Health. 1999 ; 11: 1-3
36. Speroff L, Fritz MA Clinical Gynecologic Endocrinology and Infertility. 7 th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2003. Philadelphia, PA: Lippincott Williams & Wilkins ; 2003:
37. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol. 1992 ; 80: 827-830
38. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000 ; 92: 328-332 (Pubitemid 30117736)
39. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006 ; 55: 103-115 (Pubitemid 44307491)
40. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Picker JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001 ; 75: 1065-1079 (Pubitemid 32522600)
41. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002 ; 287: 2668-2676 (Pubitemid 34533545)
42. Yasui T, Uemura H, Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. J Med Invest. 2003 ; 50: 136-145 (Pubitemid 38019760)